Journey Medical Corporation (DERM)
NASDAQ: DERM · Real-Time Price · USD
5.19
+0.05 (0.97%)
Feb 21, 2025, 4:00 PM EST - Market closed
Journey Medical Revenue
Journey Medical had revenue of $14.63M in the quarter ending September 30, 2024, a decrease of -57.64%. This brings the company's revenue in the last twelve months to $57.77M, down -27.69% year-over-year. In the year 2023, Journey Medical had annual revenue of $79.18M with 7.48% growth.
Revenue (ttm)
$57.77M
Revenue Growth
-27.69%
P/S Ratio
1.78
Revenue / Employee
$1,409,049
Employees
41
Market Cap
108.42M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 79.18M | 5.51M | 7.48% |
Dec 31, 2022 | 73.67M | 10.54M | 16.69% |
Dec 31, 2021 | 63.13M | 18.60M | 41.78% |
Dec 31, 2020 | 44.53M | 9.61M | 27.52% |
Dec 31, 2019 | 34.92M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
DERM News
- 17 days ago - Stock Picks From Seeking Alpha's January 2025 New Analysts - Seeking Alpha
- 23 days ago - Journey Medical Corporation: Emrosi's Launch Could Be A Turning Point - Seeking Alpha
- 4 weeks ago - Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea - GlobeNewsWire
- 3 months ago - Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 3 months ago - Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea - GlobeNewsWire
- 4 months ago - Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference - GlobeNewsWire
- 5 months ago - Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - GlobeNewsWire
- 5 months ago - Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference - GlobeNewsWire